China approves HUTCHMED and Innovent combo therapy for advanced kidney cancer
HUTCHMED (NASDAQ:HCM) and Innovent Biologics jointly announced that China’s National Medical Products Administration has approved the combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab injection) for the treatment of adults with advanced kidney cancer.











